The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer. The bifunctional PD-L1/TGF-β inhibitor SHR-1701, in ...

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo. Ponsegromab (PF-06946860), a GDF-15 inhibitor, increased weight gain ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.